• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Boost Interval Matters: A Randomized Phase I Study to Identify the Minimum Interval to Observe the H5DNA Influenza Vaccine Priming Effect

tetano

Editor, Senior Moderator
J Infect Dis. 2013 Apr 30. [Epub ahead of print]
Boost Interval Matters: A Randomized Phase I Study to Identify the Minimum Interval to Observe the H5DNA Influenza Vaccine Priming Effect.
Ledgerwood JE, Zephir K, Hu Z, Wei CJ, Chang L, Enama ME, Hendel CS, Sitar S, Bailer RT, Koup RA, Mascola JR, Nabel GJ, Graham BS; the VRC 310 Study Team.
Source

Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Abstract

Background. H5DNA priming was previously shown to improve antibody response to H5N1 monovalent inactivated vaccine (MIV) with a 24-week interval. This study defines the shortest prime-boost interval with improved response.Methods. We administered H5DNA followed 4, 8, 12, 16, or 24 weeks by MIV as compared to two doses of MIV (24-week).Results. H5DNA priming with ≥12 week MIV boost showed improved response, with positive HAI in 91% [geometric mean titer (GMT) 141-206]; compared to ≤8-week boost (55-70%; GMT 51-70) or MIV-MIV 24-week boost (44% ; GMT 27).Conclusions. H5DNA priming enhances antibody responses after an MIV boost when the interval is 12-24 weeks.

PMID:
23633407
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23633407
 
Back
Top Bottom